| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAIR1 |
| Uniprot No | Q6GTX8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-163aa |
| 氨基酸序列 | QEEDLPRPSISAEPGTVIPLGSHVTFVCRGPVGVQTFRLERESRSTYNDT EDVSQASPSESEARFRIDSVSEGNAGPYRCIYYKPPKWSEQSDYLELLVK ETSGGPDSPDTEPGSSAGPTQRPSDNSHNEHAPASQGLKAEHVDHHHHHH |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LAIR1重组蛋白的模拟参考文献示例(仅供参考，具体文献需通过学术数据库查询)：
---
1. **文献名称**: *"Recombinant LAIR-1 Protein Suppresses Collagen-Induced T Cell Activation via Immune Modulation"*
**作者**: Smith A, et al.
**摘要**: 研究成功在大肠杆菌中表达并纯化LAIR1重组蛋白，证实其可通过结合胶原蛋白抑制T细胞活化，提示其在自身免疫疾病治疗中的潜在应用。
2. **文献名称**: *"Structural Insights into LAIR1-Collagen Interaction through Recombinant Protein Crystallography"*
**作者**: Johnson B, et al.
**摘要**: 利用X射线晶体学解析LAIR1重组蛋白与胶原的复合物结构，揭示其免疫调节功能的结构基础，为靶向药物设计提供依据。
3. **文献名称**: *"LAIR1-Fc Fusion Protein Attenuates Inflammatory Responses in Murine Sepsis Models"*
**作者**: Lee C, et al.
**摘要**: 构建LAIR1-Fc重组融合蛋白，在小鼠脓毒症模型中验证其通过阻断炎症通路减轻组织损伤的效果，表明其作为新型抗炎疗法的潜力。
4. **文献名称**: *"Recombinant LAIR1 Disrupts Malaria Parasite Immune Evasion Mechanisms"*
**作者**: Zhang Y, et al.
**摘要**: 发现疟原虫通过LAIR1介导的免疫逃逸机制，重组LAIR1蛋白可竞争性阻断病原体与宿主受体的结合，增强机体清除病原体的能力。
---
建议通过 **PubMed**、**Web of Science** 或 **Google Scholar** 检索关键词“LAIR1 recombinant protein”获取真实文献。如需具体文献协助，可提供更详细的研究方向或背景。
**Background of LAIR1 Recombinant Protein**
LAIR1 (Leukocyte-Associated Immunoglobulin-like Receptor 1) is an inhibitory immune receptor belonging to the immunoglobulin superfamily. It is primarily expressed on leukocytes, including natural killer (NK) cells, T cells, B cells, and monocytes. LAIR1 plays a critical role in modulating immune responses by interacting with collagen and other extracellular matrix (ECM) components. Upon binding to its ligands, LAIR1 transmits inhibitory signals through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain, thereby dampening excessive immune activation and maintaining immune homeostasis.
The development of recombinant LAIR1 protein stems from its potential therapeutic and research applications. Recombinant LAIR1 is typically produced using expression systems (e.g., mammalian, insect, or bacterial cells) to ensure proper folding and post-translational modifications. This engineered protein often includes the extracellular domain of LAIR1. which retains its ligand-binding capacity.
Research on LAIR1 has gained momentum due to its dual role in immunity: it not only regulates autoimmune and inflammatory diseases but is also exploited by pathogens like *Plasmodium falciparum* (malaria parasite) to evade host immunity. For instance, malaria proteins mimic collagen to bind LAIR1. suppressing immune cell activity. Recombinant LAIR1 proteins are thus used to study these interactions, develop blocking agents, or engineer LAIR1-based biologics (e.g., fusion proteins with Fc regions) to enhance immune responses in cancer immunotherapy.
Additionally, LAIR1 recombinant proteins serve as valuable tools in structural studies, ligand screening, and diagnostic assays. Their therapeutic potential is being explored in autoimmune disorders, chronic infections, and cancer, where modulating LAIR1 signaling could restore immune balance or enhance pathogen clearance. Overall, LAIR1 recombinant protein represents a promising avenue for both understanding immune regulation and developing targeted therapies.
(Word count: 298)
×
